Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01418261 · ClinicalTrials.gov registry record · NA
SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension
A NA study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- NA
- Development phase
- 535
- Enrollment target
NCT01418261: Completed NA study, sponsored by Medtronic Vascular.
NCT01418261 is a NA study that has completed, run by Medtronic Vascular. The registered enrollment target is 535 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01418261, a NA study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- NA
- Development phase
- 535 participants
- Enrollment target
Study Summary
The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system that delivers radiofrequency (RF)energy through the luminal surface of the renal artery.
Primary Outcome
Primary Effectiveness Outcome Measure
Interventions
- DEVICE Renal denervation (Symplicity Catheter System)
- DIAGNOSTIC_TEST Renal angiogram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2011-09 |
| Est. Completion | 2017-02-17 |
| Phase | NA |
What the finished NCT01418261 record still lists
NCT01418261 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which Renal denervation (Symplicity Catheter System) is the first listed.
NCT01418261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01418261 about?
NCT01418261 is a clinical study titled "SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension". The Symplicity HTN-3 study is a, multi-center, prospective, single-blind, randomized, controlled study of the safety and effectiveness of renal denervation in subjects with uncontrolled hypertension. Bilateral renal denervation will be performed using the Symplicity Catheter - a percutaneous system ...
What is the current status of trial NCT01418261?
This trial is currently completed. It is a NA study. The enrollment target is 535 participants. The study started on 2011-09. Estimated completion is 2017-02-17.
What interventions are being tested in trial NCT01418261?
The interventions under investigation include: Renal denervation (Symplicity Catheter System) (DEVICE), Renal angiogram (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01418261?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01418261's enrollment target sits among peer trials
535 188th of 2000 higher than 1,813 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia